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Abstract 
Purpose  
To develop a statistical method of combining multimodal MRI (mMRI) of adult glial brain tumours 
to generate tissue heterogeneity maps that indicate tumour grade and infiltration margins. 
Materials and Methods  
We performed a retrospective analysis of mMRI from patients with histological diagnosis of glioma 
(n=25).  
1
H Magnetic Resonance Spectroscopic Imaging (MRSI) was used to label regions of 
“pure” low- or high-grade tumour across image types. Normal brain and oedema characteristics 
were defined from healthy controls (n=10) and brain metastasis patients (n=10) respectively. 
Probability density distributions (PDD) for each tissue type were extracted from intensity 
normalised proton density and T2-weighted images, and p and q diffusion maps. Superpixel 
segmentation and Bayesian inference was used to produce whole-brain tissue-type maps. 
Results  
Total lesion volumes derived automatically from tissue-type maps correlated with those from 
manual delineation (p<0.001, r = 0.87). Large high-grade volumes were determined in all grade III 
& IV (n=16) tumours, in grade II gemistocytic rich astrocytomas (n=3) and one astrocytoma with a 
histological diagnosis of grade II. For patients with known outcome (n=20), patients with survival 
time < 2 years (3 grade II, 2 grade III and 10 grade IV) had a high-grade volume significantly 
greater than zero (Wilcoxon signed rank p<0.0001) and also significantly greater high grade volume 
than the 5 grade II patients with survival > 2 years (Mann Witney p=0.0001). Regions classified 
from mMRI as oedema had non-tumour-like 
1
H MRS characteristics. 
Conclusions  
1
H MRSI can label tumour tissue types to enable development of a mMRI tissue type mapping 
algorithm, with potential to aid management of patients with glial tumours.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Keywords: Magnetic resonance spectroscopy (MRS); multimodal MRI; glioma; nosologic 
imaging; pattern recognition; 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
Abbreviations 
tCho total cholines 
tCr total creatines 
CSF cerebrospinal fluid 
FLAIR fluid attenuated inversion recovery 
GII grade II 
GIII grade III 
GIV grade IV 
Glx glutamate & glutamine 
GM grey matter 
MET metastasis 
mMRI multimodal MRI 
MRS magnetic resonance spectroscopy 
MRSI magnetic resonance spectroscopic imaging 
NAA N-acetyl aspartate 
Ne necrosis 
PDD probability density distribution 
PDw proton density weighted 
PDn proton density normalised 
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PRESS point resolved spectroscopy 
RGB red green blue 
ROI region of interest 
T2w T2 weighted 
T2n T2 normalised 
VO vasogenic oedema 
WM White matter 
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1. Introduction  
Gliomas are the most common primary brain tumour and have heterogeneous patterns of infiltrative 
growth [1]. Determination of glioma grade, identifying viable tumour core and infiltration margins 
are paramount for optimal patient management. Histopathological grading and genetic phenotyping 
of targeted surgical biopsy determines first line treatment [2], however this cannot provide spatial 
information which is essential for subsequent radiotherapy planning and to assess treatment 
response. While conventional MRI does indicate likely tumour grade [3], it fails to determine the 
extent of tumour infiltration into surrounding normal appearing brain [4]. This is reflected in current 
radiotherapy treatment guidelines, recommending fixed irradiation margins of 2-3cm beyond T1-
weighted contrast enhancement for high-grade gliomas [5] that aims to also irradiate and treat any 
infiltrative tumour tissue that is present. Consequently, such generalised radiation margins can 
result in “overtreatment” of healthy brain tissue, under treatment of tumour infiltration and hamper 
urgently needed dose-escalation strategies targeted to the macroscopic tumour volume rather than a 
generalised clinical target volume. These current shortcomings in high grade glioma treatment are 
illustrated by the fact that almost all high grade gliomas recur, with around 80% showing recurrence 
in the high dose fields and 20% showing more distant recurrence associated with tumour infiltration 
beyond this clinical target volume [6].    
Techniques such as perfusion weighted imaging (PWI) [7], diffusion tensor imaging (DTI) [8], and 
1H magnetic resonance spectroscopy (MRS) [9-11] provide additional information regarding 
tumour grade and infiltration. Multimodal magnetic resonance imaging (mMRI) combined with 
pattern recognition techniques can provide nosologic images that identify likely tissue-type [7, 12-
14]. Development of mMRI classifiers requires tissue-type labelling of training data, however, 
expert labelling is subjective and often limited to small regions of high label confidence [7, 14]. 
Magnetic resonance spectroscopy imaging (MRSI) has been used to create tissue-type maps both as 
a single modality [9, 10] and in combination with MRI [12-14]. 1H MRS shows good accuracy for 
classifying glioma grade [15] and MRSI has been used to map underlying tissue-type components 
for glial tumours [10]. However, compared to MRI, MRSI is technically difficult, has long 
acquisition times and does not easily provide whole brain coverage. 
The goal of this study was to develop an analysis method to combine mMRI to provide tissue 
classification and thus determine the grade, spatial extent and heterogeneity of brain tumours. Here 
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we present the proof-of-principle in a cohort of 25 low grade and high grade glioma patients. Our 
approach called tissue-type analysis, uses an expandable Bayesian analysis of mMRI data. Previous 
Bayesian tissue segmentation techniques have assumed Gaussian probability distributions in 
application to MRI data (e.g. [16, 17]), and often use spatial priors. The novel technique applied in 
our study is not limited by the underlying assumptions of Gaussian statistics and does not require 
tissue spatial priors – a particular advantage in tissue segmentation of tumours that are 
heterogeneous in location and presentation.  
We use non-Gaussian, non-spatial priors constructed from the properties of mMRI. In an initial 
step, MRSI is used to objectively define regions of pure high-grade and low-grade glial tumour 
tissue from which the distributions of isotropic diffusion, p, anisotropic diffusion, q, proton density 
weighted (PDw) and T2-weighted (T2w) intensities associated with these tissue types are extracted. 
The image intensity distributions within this 4D space are used to provide prior tissue-type 
probability density distributions (PDDs) for input to a Bayesian classification scheme that generates 
whole brain tissue probability maps. We used isotropic, p and anisotropic, q diffusion maps as input 
data for the tissue-type technique as they have been shown to identify tumour infiltration [8, 18]. 
Furthermore, in this pilot study we also use intensity normalised proton density weighted (PDn) and 
T2-weighted (T2n) images as input data, as they represent surrogates of fully quantitative MRI. In 
this study we demonstrate the potential of our tissue-type mapping technique to identify tumour 
grade and its spatial distribution and investigate the relationship between high-grade tissue volumes 
identified by the tissue-type mapping technique and patient survival. 
2. Methods  
2.1. Subjects  
35 brain tumour patients with histopathological diagnosis (mean age 53 ± 13 years) were studied 
retrospectively: WHO grade II (5 diffuse astrocytomas, 3 gemistocytic rich astrocytomas, 1 
oligoastrocytoma); WHO grade III (3 anaplastic astrocytoma, 1 anaplastic oligoastrocytoma); WHO 
grade IV (11 glioblastomas, 1 gliosarcoma); and 10 brain metastases (MET). (Note: these subtypes 
reflect histopathological terminology at the time of original diagnosis, whereas in the current WHO 
2016 classification [19], what may have been defined as oligoastrocytoma is now defined as either 
astrocytoma or oligodendroglioma according to 1p19q status). Patients were newly diagnosed and 
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treatment naive. The 2D MRSI data of the 25 glioma patients has been previously analysed [10, 20]. 
We used previous results [10] to select MRSI voxels corresponding to pure tumour (see section 
2.4.) in the current study. MRI data for characterisation of healthy brain tissue was obtained from a 
subset of 10 age-matched individuals that were previously scanned using the same mMRI protocol 
as part of the St George’s Neuroimaging in the Elderly (GENIE) study [21]. All data were obtained 
in accordance with local ethics procedures. 
2.2. Magnetic resonance image  acquisition and pre-processing 
Multimodal MRI data was acquired on a 1.5-T Signa Horizon (GE Medical Systems, Milwaukee, 
WI, USA) equipped with 22 mTm
-1
 gradients using a quadrature head coil and comprised standard 
clinical MRI with the addition of DTI and 2D 1H MRSI. 
Whole brain 3D T1-weighted images were acquired with a gradient echo with field of view (FOV) 
240 mm  240 mm  186 mm and 0.9375 mm in-plane resolution with 1.5 mm slice thickness with 
data acquired pre- and post- intravenous injection of a Gd-based contrast agent.  
Whole brain T2-weighted FLAIR images were acquired with FOV 220 mm  220 mm, a 256  256 
acquisition matrix
 
across 29 slices with 5mm thickness (TE=133 ms, TR=9000 ms, TI=2200 ms).    
PD-weighted (PDw) and T2-weighted (T2w) images were acquired using a dual spin echo sequence 
(TE=14/98 ms, TR=3500 ms) with FOV of 240 mm  240 mm, a 256  256 acquisition matrix, and 
29 slices with 5 mm thickness. Image intensity normalisation using histogram matching was applied 
across the entire dataset of T2w and PDw images to enable semi-quantitative comparisons of T2w 
and PDw images between patients [14]. Prior to intensity normalisation the T2w and PDw images 
were skull stripped using Brain Extraction Tool (FMRIB software library, Oxford University, 
United Kingdom, https://fsl.fmrib.ox.ac.uk/fsl/, BET, [22]) and the intensity histograms were 
translated and scaled to minimise the L2 norm of the difference to a randomly chosen reference 
T2w and PDw histogram respectively  [14, 23]. Intensity normalised T2w and PDw images are 
referred to as T2n and PDn throughout this manuscript.  
DTI data was acquired using a diffusion-weighted spin-echo with an echo-planar imaging sequence 
(TE=80ms, TR=7000ms) in 12 diffusion gradient directions with b=1000 s/mm
2
 and four averages. 
Eight b=0 s/mm
2
 images were also acquired. Contiguous whole brain coverage was obtained (50 
slices 2.8 mm thick) using two interleaved acquisitions with slice spacing 2.8 mm (FOV 240 mm  
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240 mm using a 96  96 acquisition matrix). DTI data was interpolated to a 256  256 matrix by 
zero filling to provide an in-plane voxel resolution of 0.9375mm
2
. Motion and eddy current 
correction was applied and the diffusion tensor was computed at each voxel. Isotropic p and 
anisotropic q diffusion were used to quantify isotropic and anisotropic diffusion tensor components, 
respectively, and were calculated as proposed by Peña et al. [24]. Data were skull stripped using 
BET [22]. 
MRSI data was acquired with the GE PROBE-SI protocol using PRESS localisation (TE=30ms, 
TR=2000ms), outer volume suppression and a full k-space 16  16 phase-encoded matrix for a 
single slice with nominal voxel size of 13.75 mm  13.75 mm  15 mm. MRSI data was zero filled 
to 32  32 voxels resulting in a nominal voxel size of 6.875 mm  6.875 mm  15 mm. Only MRSI 
voxels fully within the PRESS excitation volume were used for analysis using LCModel [25] as 
described in section 2.4. 
2.3 Magnetic resonance image co-registration 
To allow voxel-wise multimodal analysis all MRI for each patient were co-registered and resliced to 
the orientation and spatial resolution of the DTI data. The T2n image was co-registered and resliced 
to the DTI (i.e. to the image without diffusion sensitisation, b=0 s/mm
2
) using a rigid body 
transform estimated using normalised mutual information in Statistical Parametric Mapping 
software (SPM12, http://www.fil.ion.ucl.ac.uk/spm/). The same rigid transform was applied to the 
PDn image, ensuring all images were aligned to the DTI data.  The T1w and FLAIR images were 
also co-registered and resliced to the b=0 s/mm
2
 image using a rigid body transform estimated using 
normalised mutual information in SPM. Although FLAIR images have generally superseded dual-
echo for radiological assessment [26] and post-contrast T1w images are a key diagnostic modality, 
we extracted the prior PDDs from the p, q, T2n, and PDn images only, as a precursor to fully 
quantitative T2 and PD acquisitions in future studies.  
2.4. Constructing a priori probability density distributions for each tissue type   
Prior probability density distributions (PDDs) were generated from p, q, T2n, and PDn images for 
the following tissue-types: GIV glioma, GII glioma, GIV necrotic tissue, vasogenic oedema, normal 
grey matter, white matter and cerebrospinal fluid. Tissue-type PDDs were derived from mMRI 
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within regions with the highest confidence of being a single tissue class. The following regions of 
interest (ROIs) were selected. 
Tumour tissue ROIs: Within each MRSI voxel, LCModel was used to linearly decompose the 1H 
spectrum into normal brain, grade II (GII) and grade IV (GIV) components [10]. GII and GIV ROIs 
were automatically defined from MRSI voxels for which the spectrum was comprised of greater 
than 90% GII or greater than 90% GIV glioma components from GII and GIV gliomas respectively. 
Normal tissue ROIs: Multichannel tissue segmentation (SPM12, 
http://www.fil.ion.ucl.ac.uk/spm/) was applied to T2n and PDn images of normal controls. A 
probability threshold of 0.95 was used to create binary maps of grey matter (GM), white matter 
(WM) and cerebrospinal fluid (CSF).  
Vasogenic oedema ROIs: Manual ROIs were drawn by an expert (neurosurgeon TLJ) around 
visible oedema on p diffusion maps of the MET cases, with specific exclusion of the tumour core, 
using MRIcro (http://www.mccauslandcenter.sc.edu/crnl/tools).  
The tissue specific ROIs described above were used to extract p, q, T2n, and PDn voxel intensities. 
The necrotic tissue ROIs was created by extracting mMRI data from GIV MRSI voxels with p > 
4×10
-3
 mm
2
/s. The tissue PDDs were generated by mapping the mMRI ROI voxel intensities to a 
4D space with axes represented by p, q, T2n, and PDn data. Each 4D histogram was normalised to 
unit volume with 50 bins along each axis, thus creating a 4D PDD for each tissue-type. Figure 1 
illustrates the PDD computation process for p and q data from a pure GIV voxel. PDDs for GM, 
WM, vasogenic oedema (VO), GII, GIV and necrotic tissue (Ne) are shown in Figure 2 (the PDDs 
for CSF are not shown). The 4D tissue PDDs were used as a priori information in a Bayesian model 
to compute tissue probability maps. 
2.5 Computation of tissue probability maps 
Bayes’ theorem was used to calculate the posterior probability P(Ci|X) of each voxel intensity X, 
belonging to tissue class Ci where i{1,…,7} using, 
 
   
   

j
jj
ii
i
CXpCP
CXpCP
XCP
|
|
| ,      Eq.1 
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where P(Ci) is the a priori probability of a voxel intensity X, belonging to tissue class Ci, and 
p(X|Ci) is the probability of tissue class Ci for a specific value of X. In this study, X =(X1, X2, X3, X4) is 
a feature vector comprising the four mMRI intensities (i.e. p, q, T2n & PDn, see red rectangle in 
Figure 3a). The a priori probabilities were calculated from the 4D tissue PDDs as follows, 
 
 

j
j
i
i
CXp
CXp
CP
|
|
)( .       Eq. 2 
Tissue probability maps (Figure 3b) were computed for all tumour patients on a voxel-wise basis 
using the data from the four image modalities. 
2.6 Superpixel segmentation – identification of local homogeneous tissue regions  
Superpixels are polygonal shaped regions for which the image voxels within them have similar 
imaging characteristics and can be used to aid tissue-type classification [27]. Here they are used to 
provide local averaging of the probability maps to reduce the presence of spurious tissue-type 
classifications arising from noise. Superpixels were created using the Simple Iterative Clustering 
(SLIC) algorithm [28] implemented as jSLIC [29] in Fiji ([30], http://fiji.sc/) where the 
minimisation function includes spatial and intensity information across three image channels. We 
selected PDn, FLAIR, and p images as the minimum dataset that gave a segmentation with visually 
distinct tissue-types within each superpixel. FLAIR was included to ensure the superpixel 
segmentation correctly distinguished between CSF and oedema. The q diffusion image was 
excluded because of its heterogeneity within white matter. Prior to segmentation the image data was 
interpolated to a 1024 by 1024 matrix, and the default jSLIC values of grid-size 30 and 
regularisation parameter 0.2 were used, which ensured the superpixel contours followed the major 
normal and pathological tissue boundaries. The superpixel mesh was then mapped onto the raw 
probability maps (Figure 3c) from which the average tissue type was calculated within each 
superpixel. 
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2.7 Tissue-type colour maps 
Probabilities provided by the voxelwise tissue probability maps (Figure 3b) were averaged within 
each superpixel (Figure 3c) and normalised within each superpixel to sum to 1. These tissue-type 
probabilities were used to automatically segment the entire lesion using the following inequality, 
p(VO)+ p(GII)+ p(GIV)+ p(Ne) > 0.5,     Eq. 3 
and extracting the largest connected 3D superpixel component. Superpixels were then coloured 
according to a RGB colour scheme (Figure 3d) to identify high-grade cellular dense tissue (red), 
low-grade core and tumour infiltrated tissue (green), necrotic tissue (blue) or vasogenic oedema 
(black). Colour channels were assigned according to: 
Red:  p(GIV) 
Green: p(GII)        Eq. 4 
Blue: p(Ne) 
Resulting colours were normalised to unit length and intensity modulated according to the 
probability of presence of tumour tissue (i.e. p(GII)+ p(GIV)+ p(Ne)).  The modulation technique 
ensures regions of vasogenic oedema appear black in the colour map. An example tissue-type 
colour map is shown in Figure 3e. The colour wheel associated with our tissue-type mapping and its 
interpretation is illustrated in Figure 4.  
2.8. Evaluation of the tissue-type mapping technique  
The results of this study were evaluated in three ways to assess their validity: 
i. The tissue proportions estimated by the mMRI tissue-type technique were directly 
compared to those obtained by 1H MRSI using LCModel tissue type analysis [10]. To 
enable direct voxel-by-voxel comparison of tissue-type probabilities as determined by MRI 
and MRS the voxelwise tissue probability maps (Figure 3b) were resampled to match the 
MRSI location and resolution.  
Tissue probabilities for non-tumorous brain (p(GM) + p(WM) + p(CSF) + p(VO)), low-
grade tissue (p(GII)), and high-grade tissue (p(GIV)+p(Ne)) computed from the tissue 
probability maps were compared with the LCModel MRS decomposition into normal brain, 
GII and GIV components. The Distance Correlation technique [31] was used to investigate 
the relationship between these two 3D spaces (i.e. the two subspaces with axes represented 
by normal brain, low-grade and high-grade tissue values). Statistical analysis was 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
performed after exclusion of the training MRSI voxels (i.e. without the mMRI data that 
were used to generate the a priori tumour tissue PDDs). 
ii. Total lesion volume calculated from manually drawn margins on FLAIR images was 
compared with the abnormality volume automatically delineated by the tissue-type mapping 
technique. Comparison of ROI volumes was performed using Pearson’s correlation with 
systematic volume differences assessed using a Bland-Altman analysis. Similarities 
between the ROIs were evaluated using the Dice coefficient, Jaccard index and Overlap 
coefficient. 
iii.  The tissue-type mapping technique provides the volume of high-grade tumour tissue within 
a lesion according to a given probability threshold. To evaluate the technique we compared 
the estimated high-grade tissue volumes extracted using a probability threshold of 
p(GIV)>0.5 with the clinically defined grade from routine histology and patient survival. 
 
3. Results  
3.1. Probability density distributions  
Figure 2 shows 2D projections from the 4D PDDs computed from tissue specific ROIs for WM, 
GM, VO, GII, GIV and Ne tissue types. In (p,q) diffusion space (Figure 2a), PDDs are non-
Gaussian except for WM and VO and within healthy tissues the PDDs show less heterogeneity than 
in tumour tissue. The VO PDD has greater p and q diffusivity compared to tumour tissue. In 
(T2n,PDn) space (Figure 2b) the GM and WM distributions are well-defined and clearly separated, 
confirming accurate tissue identification and effectiveness of T2w and PDw intensity normalisation 
across subjects. Abnormal tissue types are characterised by increased PDn and T2n compared to 
GM and WM, with clusters that may represent abnormal tissue subgroups within each tumour 
grade.  
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3.2. Tissue-type maps and comparison with MRSI 
Whole brain tissue-type colour maps for a GII astrocytoma and a GIV glioblastoma are shown in 
Figure 5. A low-grade tumour core surrounded by vasogenic oedema is identified for the GII 
astrocytoma case. The tissue-type map provides a 3D segmentation that identifies a whole lesion 
boundary similar to the edge of the FLAIR abnormality region both within and beyond the limit of 
the PRESS MRSI region from which the tumour PDDs were initially sampled. Within the 
glioblastoma, a high-grade tumour core (red) with necrosis (blue) surrounded by tumour infiltrated 
tissue (green) and vasogenic oedema (dark) is found. The mMRI defined high-grade tumour core 
region includes regions of T1-weighted contrast enhancement, although contrast enhanced MRI was 
not used in developing our tissue-type mapping technique. Apparent tumour infiltration (green) 
extends beyond the FLAIR hyperintensities visible in the coronal and sagittal slices (Figure 5d-e). 
Figures 6 and 7 illustrate the tissue-type segmentation and its relationship to 1H spectra within the 
PRESS MRSI localisation region for a GII astrocytoma (Figure 6a), GII gemistocytic astrocytoma 
(Figure 6b) and a GIV glioblastoma (Figure 7). The tissue-type map generated from mMRI data 
identifies regions of vasogenic oedema, low-grade and high-grade tumour tissue that are consistent 
with the associated MRSI spectra. High-grade tumour tissue regions are identified in the GII 
gemistocytic astrocytoma and GIV glioblastoma consistent with regions of T1-weighted contrast 
enhancement and high-grade tissue 1H spectra. For comparison, tissue-type maps were also 
calculated at MRSI resolution and MR spectra of selected voxels that were not used for PDD 
development are shown.   
Figure 8 shows average 1H spectra identified by mean tissue-type probabilities computed within 
each MRSI voxel. In Figure 8(a-d) the average spectra are taken from MRSI voxels with >75% 
tissue probability for: normal tissue (Figure 8a), vasogenic oedema (Figure 8b), and GII and GIV 
glioma (Figures 8c-d). Note that MRSI voxels used to define the low-grade and high-grade tumour 
PDDs priors were excluded from the average spectra shown in Figure 8 (a-f). The vasogenic 
oedema spectrum (Figure 8b) has elevated glutamate plus glutamine (Glx) and the presence of 
lactate compared to the characteristic normal brain spectrum (Figure 8a). Figures 8c and 8d show 
typical tumour metabolic profiles of reduced N-acetyl aspartate (NAA), elevated total cholines 
(tCho), reduced total creatines (tCr) and the presence of lactate. The average tCho/tCr and 
lactate/tCr ratios are greatest in high-grade gliomas. Although the PDM analysis aims to separate 
viable high grade glioma tissue and necrosis, the average MRSI spectrum for high grade glioma 
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(Figure 8d) will inevitably contain some partial volume effects with necrosis increasing the visible 
lipid and lactate proportions. For MRSI voxels with calculated tissue-type probabilities between 
75% and 50% (Figure 8e-f) the average metabolic characteristics are less well-defined in terms of 
distinct glioma grade. Average spectra from the MRSI voxels of low- and high-grade glioma that 
were used initially to calculate the mMRI tumour PDDs are shown in Figures 8g & 8h, respectively. 
These spectra show the typical metabolic profiles for low- and high-grade tissue and were used to 
define the a priori PDDs as they represent tissue with a predominant tumour grade. 
3.3. Evaluation 
We investigated whether the MRI derived tissue-type probabilities computed within each MRSI 
voxel were related to our LCModel tissue-type classification analysis [10]. The Distance 
Correlation technique [31] gave correlation coefficients of r = 0.84 across all MRSI voxels, and r = 
0.79 when MRSI voxels used to define the a priori tumour tissue PDDs were excluded. 
Comparison of total lesion volume from FLAIR images and the abnormality volume delineated by 
the tissue-type mapping show good correspondence (Figure 9) over all tumour grades (Pearson’s 
correlation coefficient, p<0.001, r=0.87). Bland-Altman analysis revealed that the automatically 
segmented volumes were generally larger than those determined by manual delineation, especially 
for high-grade gliomas (see Figure 9b). Good correspondence between manually and automatically 
segmented lesion boundaries was obtained: Dice coefficient 0.77±0.13, Jacard index 0.64±0.14, 
Overlap coefficient 0.9±0.08.  
High-grade tissue volumes estimated from the tissue-type analysis for all superpixels with 
p(GIV)>0.5 are presented according to histopathological grade in Table 1. GII astrocytoma and GII 
oligoastrocytoma cases are characterised by an extremely low volume of high-grade tissue (range 0-
0.3 ml), but include one outlier with 49 ml of high-grade tissue. GII gemistocytic rich astrocytoma, 
GIII anaplastic astrocytoma and GIV glioblastoma all had comparatively greater volumes of high-
grade tissue. Comparison of high-grade tumour volume with patient survival (where available) is 
shown in Table 2. Patient survival was ≥ 2 years for GII tumours, except for one GII astrocytoma (< 
1 year) and the two GII gemistocytic rich astrocytomas (1 to 1.5 years). GIII anaplastic astrocytoma 
and Grade IV glioblastoma cases were characterised by greater volumes and poorer survival (< 1.5 
years). Patients with survival time < 2 years (3 grade II, 2 grade III and 10 grade IV) had a high-
grade tissue volume significantly greater than zero (Wilcoxon signed rank p<0.0001) and volumes 
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significantly greater than those of the 5 GII patients with survival > 2 years (Mann Witney 
p=0.0001). One GII astrocytoma showed contrast-enhancement (CE), but had negligible high-grade 
tissue volume (0.3ml) and survival > 2years. Conversely the GII astrocytoma with poor survival (< 
1 year) showed no CE but a large high-grade tissue volume (46ml). 
4. Discussion  
Our results indicate that mMRI signal intensities and their distributions can be used directly via a 
multi-dimensional Bayesian framework to grade and create tissue-type maps of glial tumours. In a 
single dimension of one MRI parameter there can be extreme overlap between different tissue 
PDDs, but a multi-dimensional framework allows cluster separation as can be observed for the low- 
and high-grade tumour tissue clusters in the T2n – PDn space, for which there is correlated 
variability but also cluster separation (Figure 2b). Furthermore the probability functions of Eqs 1-2 
can be expanded to incorporate other tissue classes or imaging modalities to potentially improve 
classification simply by addition of new PDDs or expanding the PDD dimensions respectively. 
A current general strategy is to incorporate MRSI as an addition to an mMRI protocol for aiding 
brain tumour characterisation [7, 14, 32]. By using 1H MRS and its unique metabolic information, 
we more objectively label tumour regions for extraction of image parameter PDDs as compared to 
manual labelling [7, 14]. The strong correlation of the tissue estimates obtained from the tissue-type 
analysis and those obtained from the LCModel tissue type analysis [10], indicates, similar 
information to that is contained within MRS data can be extracted from our mMRI data. This major 
finding might enable us in future to create comprehensive tissue PDDs from a training set of cases 
with a full MRI protocol including MRSI, which could then be applied to cases who have not 
received a MRSI exam.  
To the best of our knowledge, this study is the first to use 1H MRSI purely as a tool for tissue type 
labelling to enable mMRI tissue classification over the whole brain despite the initial restricted 1H 
MRSI coverage. Within the MRSI volumes, classification accuracy was assessed with average 
spectra. Voxels with mMRI derived probabilities > 75% for either low- or high-grade glioma tissue 
had average spectra (Figs 8c,8d) in good agreement with the average 1H spectra for voxels used for 
the original definition of the PDD (Figs 8g,8h).  The superpixel classification maps have more 
clearly defined tissue-types in their core than the MRSI voxels, which have partial volume estimates 
across several superpixels due the large MRSI slice thickness and since the MRSI grid will not 
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necessarily match with actual tissue boundaries, whereas the superpixel boundaries are based on the 
image characteristics (Figs 6b & 7). Hence for MRSI voxels with single tissue-type probabilities of 
50% to 75%, the average spectra show mixed tumour grades (Figs 8c, 8d). Voxels classified with 
probability >75% oedema do not have elevated tCho/tCr compared to normal brain (Fig 8a,8b) 
suggesting there is no tumour infiltration [11]. The elevation of Glx could be related to excitoxicity 
[33] due to tumour generated lactate diffusing into the peritumoural space.  
Over the whole brain, the mMRI classification derives a total lesion volume that correlates well 
with manual delineation, but is slightly larger (Fig 9). However, the lesion volume is determined by 
the chosen probability threshold for classifying abnormal tissue. A longitudinal study is needed to 
determine the optimal probability threshold for mapping tumour infiltration beyond the clinical 
target volume used for post-surgical radiotherapy dose planning. 
There is good evidence that metabolic information from 1H MRSI has applications for tumour 
biopsy targeting, radiotherapy planning [9] and to aid prognosis [34]. Mapping the MRI 
characteristics from tissue regions with specific 1H MRS profiles provides a surrogate metabolic 
marker in the form of a Bayesian analysis of mMRI. The results from our Bayesian model and PDD 
priors are also consistent with observations that diffusion and T2 parameters have potential to detect 
tumour infiltration [8, 18, 35]. The presence of mMRI derived high-grade tumour volume showed 
good agreement with overall patient survival (Table 2), albeit a prospective evaluation with a larger, 
longitudinal dataset is needed. High-grade mMRI characteristics were observed in all three 
gemistocytic tumours, in keeping with their more aggressive behaviour compared to other low-
grade gliomas [36], and also in a non-enhancing GII astrocytoma of a patient with < 2yrs survival. 
Such identified high-grade volumes may present promising treatment targets for future studies using 
dose escalation [9, 37] or radiosurgery [38].  
There are limitations to this current retrospective study, which is on a small dataset, and does not 
use the 2016 WHO classification system with genetic subtypes [19]. Specific MRI characteristics 
can be related to certain genetic subtypes [39], and in future work our tissue type probability 
distributions need to reflect any variability between these subtypes.  For example, our automated 
tissue-type segmentation could be used to provide direct input to other classification schemes that 
use volumetric [40] or textural [20] features for detecting tumour (sub)types with varied prognosis. 
Further work also requires validation using separate datasets for extracting the PDDs and for testing 
the classification and prognostic values of the methodology. Nevertheless, there are aspects of 
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independent validation within our current analysis. GIV tissue characteristics were only extracted 
from GIV gliomas, whereas we detected likely high-grade regions within one GII astrocytoma, 
three GII gemistocytic astrocytomas, and four GIII tumours, with each of these patients showing 
poor survival (i.e. < 1.5 yrs). In addition, we have 1H MRSI data that supports a classification of 
oedema in gliomas (Fig 8b) for which the original mMRI tissue characteristics of oedema were 
extracted from a separate metastatic tumour data set. Further work is needed to more fully validate 
the predictive value of our classification scheme when it detects high-grade and low-grade regions 
beyond the contrast-enhanced region using longitudinal studies. Finally, we used PDn and T2n 
images that are only semi-quantitative and so contain mixed weighting. New MR fingerprinting 
methods [41] will aid rapid acquisition for creation of T2 relaxation time and proton density maps, 
and this will enable rational development of protocols that would allow application of the method in 
multi-site trials and improve clinical applicability. In addition, information from other quantitative 
imaging methods, such as dynamic susceptibility contrast (DSC) MRI, which is of known value to 
aid tumour grading [42], can be straightforwardly incorporated into Eq. (1) and may further 
improve the tissue classification accuracy. 
In conclusion, a mathematically intuitive method for using mMRI to infer the likely tissue-type of 
glial brain tumours has been described, which can be readily expanded to include other imaging 
modalities and tissue-types. Tumour tissue-type mapping with multimodal MRI may aid 
management of patients with glial tumours by delineating viable tumour from oedema and normal 
brain to aid targeted biopsy, surgical planning and radiotherapy dose-planning, as well as prognosis 
for patient survival. 
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Figures 
 
Figure 1: Schematic illustration showing the extraction of p and q diffusion imaging information 
from a region of interest defined by MRSI for a GIV voxel to create PDDs. The green ROI 
represents the metabolite spectrum for an MRSI voxel with pure GIV metabolic characteristics (far 
left). All imaging voxels within this ROI are identified on the p and q diffusion maps. Over the 
cohort of high-grade tumour patients the (p,q) information within all MRSI defined high-grade 
regions is represented as a 2D histogram distribution (far right), where red represents the highest 
probability density. This histogram is a 2D projection of the full 4D probability density distribution 
used in our classification scheme. The 2D probability density distribution (far right) contains 
distinct tissue sub-types of heterogeneous, but cellular, high-grade tumour, and of necrotic tissue 
(which has a higher magnitude of isotropic (p) diffusion).  
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Figure 2: 2D projections of the 4D tissue-type probability density distributions (PDDs) are shown 
in (a) the (p,q) plane, and (b) the (PDn,T2n) plane for each tissue type. Well-defined clusters are 
identified for white matter and grey matter in the (PDn,T2n) plane indicating an accurate intensity 
normalisation across the imaging data. High-grade tumour data is separated into sub-types of 
cellular tumour and necrotic tissue on the basis of the magnitude of the isotropic (p) diffusion 
parameter. The low-grade and necrosis PDDs show heterogeneous distributions with multiple 
clusters identified in the (PDn,T2n) PDDs that may indicate different tissue sub-tissue types. 
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Figure 3: Illustration of the method for computation of tissue-type maps. (a) Data acquisition 
included T1w, T2w and PDw, FLAIR and diffusion tensor images (from which isotropic p and 
anisotropic q maps were computed). All acquired images were co-registered and resliced to the DTI 
space. (b) p, q, T2-weighted and PD-weighted images (red box) were used to compute voxelwise 
tissue probability maps by application of Bayesian statistics and tissue-type prior probability density 
distributions. Tissue probability maps were computed for grey matter, white matter, cerebrospinal 
fluid (CSF), vasogenic oedema, low-grade tissue, high-grade tissue and necrosis. (c) p, FLAIR and 
PD-weighted images (yellow box) were used to compute the superpixel map. The superpixel spatial 
resolution was chosen to identify major tissue boundaries. (d) Mean tissue probabilities were 
calculated within each superpixel and were used to identify high-grade tumour tissue (i.e. p(GIV)) 
shown in red, low-grade core or tumour infiltrated tissue (i.e. p(GII)) in green, and necrotic tissue 
(p(Ne)) in blue. (e) The composite RGB tissue-type colour map generated by the images illustrated 
in (d) is shown overlaid on the FLAIR image and provides a visual tissue-type assessment for all 
superpixels that contain abnormal tissue (i.e. p(VO) + p(GII) + p(GIV) + p(Ne) > 0.5) . Red regions 
correspond to high-grade tissue, green regions to low-grade or tumour infiltrated tissue, blue 
regions to necrotic tissue and black regions to vasogenic oedema. A colour wheel showing all 
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possible tissue-type colours is illustrated in Figure 4. 
 
Figure 4: Colour wheel indicating the tissue types and partial volume information represented by 
the tissue-type colour maps. Red represents high-grade tissue, green - low-grade or infiltrated tissue, 
blue – necrotic tissue, and black – vasogenic oedema. Partial volume voxels are represented as 
colour mixtures such that yellow indicates partial volume of high-grade and low-grade/infiltrated 
tissue, magenta – partial volume of high-grade and necrotic tissue, and cyan – partial volume of 
low-grade/infiltrated tissue and necrosis. The colour scheme is consistent with low- and high-grade 
core tissue having distinct colour coding since their mMRI characteristics are different, whereas 
tissue infiltrated by high-grade tumour becomes indistinguishable in mMRI characteristics from 
low-grade tumour at low tumour partial volumes.  
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Figure 5: Whole brain 3D tissue-type maps of a grade II astrocytoma and grade IV glioblastoma. 
The astrocytoma example shows (a) FLAIR and (b) tissue-type colour maps in coronal, sagittal and 
axial slices through the tumour. The tissue-type colour map shows the extent of the tumour and 
identifies vasogenic oedema (black) surrounding a low-grade tissue tumour core (green). The 
margins of MRSI data acquisition are shown by the yellow lines on the tissue-type colour maps. 
The glioblastoma example shows (c) T1-weighted + Gadolinium contrast agent, (d) FLAIR and (e) 
tissue-type colour maps. The tissue-type map shows the extent of the tumour abnormality and 
includes the T1-weighted and FLAIR abnormality.  With the proposed color scheme, regions of 
tumour infiltration are represented as green, with regions exhibiting high-grade tumour features in 
red, necrosis in blue and vasogenic oedema as black. In (e) the whole of the green margin zone must 
be interpreted as tumour infiltration arising from a high-grade core. 
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Figure 6: Comparison of tissue-type colour maps and MRSI data for (a) a GII astrocytoma and (b) 
a GII gemistocytic rich astrocytoma. MRSI spectra are shown for voxels with predominantly low-
grade, high-grade and vasogenic oedema as identified from probabilities computed by the MRI 
tissue-type analysis after resampling to the MRSI grid. Tissue-type probabilities are given for each 
illustrated metabolite spectrum. The tissue-type colour map is applied to the MRSI voxel grid and 
represents the mean tissue-type probabilities computed within each MRSI voxel. The corresponding 
FLAIR images and MRI tissue-type colour maps are shown at superpixel resolution. 
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Figure 7: Comparison of tissue-type colour maps and MRSI spectra for a grade IV glioblastoma. 
Panel (a) shows MRSI spectra for voxels with normal, oedematous, low-grade and high-grade 
features as identified from probabilities computed by the MRI tissue-type analysis. The MRSI voxel 
grid is coloured based on the mean tissue-type probabilities computed within each MRSI voxel. 
Mean tissue-type probabilities are indicated as percentages for each spectrum. Panel (b) shows the 
MRI tissue-type map at superpixel resolution. Panel (c) shows the corresponding contrast enhanced 
T1-weighted (CE-T1w) image and (d) shows the FLAIR image. The region of contrast 
enhancement corresponds to the location of high-grade spectra and high-grade tissue identified by 
the tissue-type analysis in panel (b). Note that the superpixel tissue-type classification technique did 
not include data from the CE-T1w image. 
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Figure 8: Average MRSI spectra categorised according to the MRI tissue-type analysis (a-f) and 
from regions used for computing prior MRI probability density distributions for Bayesian statistical 
analysis (g,h). Mean and standard deviations are shown for each tissue-type. (a) Normal tissue 
spectrum for all MRSI voxels where p(GM) + p(WM) + p(CSF) > 0.75. (b) Vasogenic oedema 
spectrum (i.e. all MRSI voxels where p(VO) > 0.75). (c) Low-grade tissue spectrum (i.e. all MRSI 
voxels where p(GII) > 0.75). (d) High-grade tissue spectrum (i.e. all MRSI voxels where p(GIV) > 
0.75). (e) Low-grade tissue spectrum where 0.75 > p(GII) > 0.5. (f) High-grade tissue spectrum 
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where 0.75 > p(GIV) > 0.5. Spectra (g) and (h) show average spectra for the MRSI voxels used to 
identify the initial imaging probability density distributions (priors) within the tissue-type analysis 
for (g) low-grade and (h) high-grade tissue. MRSI spectra included in (g) and (h) are not included in 
spectra (a) to (f). 
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Figure 9: Scatterplots showing the relationship between lesion volumes (in millilitres) obtained 
manually by expert region drawing and automatically using the tissue-type analysis. Graph (a) 
shows the relationship between manual and automatic volumes. Pearson’s correlation coefficient 
reveals a significant positive correlation between the measurements (p<0.001, r = 0.87). Graph (b) 
shows a Bland-Altman plot of the same data with mean and 95% confidence limits shown. A single 
outlier is identified of a diffuse low-grade tumour for which the automated tissue-type volume 
underestimates the manual volume. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
Table 1: Comparison of histopathological diagnosis and grade with automatically segmented 
volume (in millilitres) of high-grade tissue obtained by the tissue-type analysis. High-grade tissue is 
identified at a probability threshold of greater than 50% (i.e. p(GIV) > 0.5). GII – grade II, GIII – 
grade III, GIV – grade IV. 
Histological diagnosis (n=25) 
High-grade tissue volume (ml) 
(mean [range]) 
GII astrocytoma (n=5) 0.15 [0,0.3] (n=4), outlier 49 (n=1) 
GII oligastrocytoma (n=1) 0 
GII gemistocytic rich astrocytoma (n=3) 6 [1,11] 
GIII anaplastic astrocytoma (n=3), GIII anaplastic 
oligoastrocytoma (n=1) 
10 [2,18] 
GIV glioblastoma (n=11), GIV gliosarcoma (n=1) 52 [4,182] 
 
 
Table 2: Comparison of patient survival time with automatically segmented volume of high-grade 
tissue and histopathological tumour grade. High-grade tissue is identified at a probability threshold 
of greater than 50% (i.e. p(GIV) > 0.5) . GII – grade II, GIII – grade III, GIV – grade IV. 
Survival time 
(n=20) 
High-grade tissue volume 
(mean [range]) 
Histological Diagnosis  
≥ 2 years 
(n=5) 
0.2 [0,0.3] 
GII astrocytoma (n=4) 
GII oligoastrocytoma (n=1)  
1 to 1.5 years 
(n=7) 
42 [7,88] 
GII gemistocytic rich astrocytoma (n=2) 
GIV glioblastoma (n=4) 
GIV gliosarcoma (n=1) 
< 1 year 
(n=8) 
45 [2,182] 
Grade II astrocytoma (n=1) 
Grade III anaplastic astrocytoma (n=2) 
Grade IV gliobastoma (n=5) 
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Highlights 
 Non-Gaussian multimodal MRI characteristics of high and low grade glioma tissue. 
 Bayesian inference of multimodal MRI derives whole brain tumour tissue-type maps. 
 Automated segmentation of normal and tumour tissue volumes. 
 Visualisation of glioma heterogeneity, infiltration, necrosis and vasogenic oedema. 
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